Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers

  • Authors:
    • Dhanashri Thorat
    • Asutosh Sahu
    • Reeti Behera
    • Kirti Lohite
    • Sanjay Deshmukh
    • Anupama Mane
    • Swapnil Karnik
    • Suhaschandra Doke
    • Gopal C. Kundu
  • View Affiliations

  • Published online on: October 1, 2013     https://doi.org/10.3892/ol.2013.1600
  • Pages: 1559-1564
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is one of the most common malignant tumors among females worldwide and remains a leading cause of cancer‑related mortality. Due to the heterogeneous clinical nature of breast cancer, it is necessary to identify new biomarkers that are associated with tumor growth, angiogenesis and metastasis. Osteopontin (OPN) and cyclooxygenase‑2 (COX‑2) are known to be overexpressed in invasive breast cancer and their overexpression is associated with aggressive histological and clinical features. The present study assessed OPN and COX‑2 expression in various subtypes of breast cancer. The expression of OPN and COX‑2 was analyzed using immunohistochemistry (IHC) in a cohort of 67 invasive ductal breast carcinoma patients. The statistical analysis was performed using standard statistical software SPSS version 18.0. The associations between OPN and COX‑2 and the human epidermal growth factor receptor type 2 (HER2)‑overexpressing and non‑HER2‑overexpressing subtypes were evaluated using the Mann‑Whitney U test. The mean OPN level was significantly higher in the HER2‑overexpressing subtype compared with the non‑HER2‑overexpressing subtype. Furthermore, the mean COX‑2 expression levels were higher in the HER2‑overexpressing subtype compared with the luminal A, luminal B or triple‑negative groups. It is well known that carcinomas overexpressing HER2/neu have a worse prognosis than luminal tumors. Hence, it may be hypothesized that an elevated expression of OPN and COX‑2 in a HER2‑overexpressing subtype may contribute to a more aggressive behavior and be used as diagnostic and prognostic markers in breast cancer.
View Figures
View References

Related Articles

Journal Cover

December 2013
Volume 6 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Thorat D, Sahu A, Behera R, Lohite K, Deshmukh S, Mane A, Karnik S, Doke S and Kundu GC: Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers. Oncol Lett 6: 1559-1564, 2013.
APA
Thorat, D., Sahu, A., Behera, R., Lohite, K., Deshmukh, S., Mane, A. ... Kundu, G.C. (2013). Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology Letters, 6, 1559-1564. https://doi.org/10.3892/ol.2013.1600
MLA
Thorat, D., Sahu, A., Behera, R., Lohite, K., Deshmukh, S., Mane, A., Karnik, S., Doke, S., Kundu, G. C."Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers". Oncology Letters 6.6 (2013): 1559-1564.
Chicago
Thorat, D., Sahu, A., Behera, R., Lohite, K., Deshmukh, S., Mane, A., Karnik, S., Doke, S., Kundu, G. C."Association of osteopontin and cyclooxygenase‑2 expression with breast cancer subtypes and their use as potential biomarkers". Oncology Letters 6, no. 6 (2013): 1559-1564. https://doi.org/10.3892/ol.2013.1600